Compare · LRCX vs NOVT
LRCX vs NOVT
Side-by-side comparison of Lam Research Corporation (LRCX) and Novanta Inc. (NOVT): market cap, price performance, sector, and recent activity on the wire.
Summary
- LRCX operates in Technology, while NOVT operates in Miscellaneous - the two are in different parts of the market.
- LRCX is the larger of the two at $347.22B, about 68.1x NOVT ($5.10B).
- Over the past year, LRCX is up 86.5% and NOVT is up 21.9% - LRCX leads by 64.6 points.
- LRCX has been more active in the news (4 items in the past 4 weeks vs 2 for NOVT).
- LRCX has more recent analyst coverage (25 ratings vs 2 for NOVT).
- Company
- Lam Research Corporation
- Novanta Inc.
- Price
- $263.91-4.88%
- $128.68-4.62%
- Market cap
- $347.22B
- $5.10B
- 1M return
- -1.95%
- -4.20%
- 1Y return
- +86.46%
- +21.87%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1984
- News (4w)
- 4
- 2
- Recent ratings
- 25
- 2
Lam Research Corporation
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products. It also provides SPEED gapfill high-density plasma chemical vapor deposition products; and Striker single-wafer atomic layer deposition products for dielectric film solutions. In addition, the company offers Flex for dielectric etch applications; Kiyo for conductor etch applications; Syndion for through-silicon via etch applications; and Versys metal products for metal etch processes. Further, it provides Coronus bevel clean products to enhance die yield; Da Vinci, DV-Prime, EOS, and SP series products to address various wafer cleaning applications; and Metryx mass metrology systems for high precision in-line mass measurement in semiconductor wafer manufacturing. The company sells its products and services to semiconductors industry in the United States, China, Europe, Japan, Korea, Southeast Asia, Taiwan, and internationally. Lam Research Corporation was incorporated in 1980 and is headquartered in Fremont, California.
Novanta Inc.
Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. Its Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products for photonics-based applications, such as industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. The company's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless, recorder, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. Its Precision Motion segment offers optical and inductive encoders, precision motors, motion control sub-assemblies, servo drives, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts.
Latest LRCX
- Lam Research Corporation Announces September Quarter Financial Conference Call
- SEC Form DEFA14A filed by Lam Research Corporation
- SEC Form DEF 14A filed by Lam Research Corporation
- Wafer Inspection Equipment Market Growth — Why AI Chip Production Is Driving Demand
- President and CEO Archer Timothy exercised 30,000 shares at a strike of $30.03 and sold $9,577,800 worth of shares (30,000 units at $319.26) as part of a pre-agreed trading plan (SEC Form 4)
- Director Mayer Bethany sold $3,007,970 worth of shares (9,557 units at $314.74) (SEC Form 4)
- Senior Vice President Varadarajan Seshasayee sold $17,406,370 worth of shares (59,750 units at $291.32) as part of a pre-agreed trading plan and exercised 39,750 shares at a strike of $39.25, decreasing direct ownership by 9% to 205,546 units (SEC Form 4)
- Chief Legal Officer Harter Ava sold $1,512,300 worth of shares (5,000 units at $302.46) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 42,462 units (SEC Form 4)
- Lam Research Announces Retirement of Michael R. Cannon and Sohail U. Ahmed from Board of Directors
- Lam Research Corporation filed SEC Form 8-K: Leadership Update
Latest NOVT
- Novanta Inc. Announces Schedule of Third Quarter 2026 Earnings Release and Conference Call
- Amendment: Novanta Inc. filed SEC Form 8-K: Financial Statements and Exhibits
- Director Secor Thomas N sold $97,859 worth of shares (663 units at $147.60) as part of a pre-agreed trading plan, decreasing direct ownership by 50% to 662 units (SEC Form 4)
- Novanta to Present at Baird Global Healthcare Conference on Tuesday, September 15, 2026
- SEC Form SCHEDULE 13G filed by Novanta Inc.
- SEC Form 10-Q filed by Novanta Inc.
- Novanta Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Novanta Announces Financial Results for the Second Quarter 2026
- Novanta Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits
- Novanta Completes Acquisition of Riverpoint Medical